Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder

Amgen said Thursday that it will acquire the small drugmaker ChemoCentryx for $4 billion to obtain a newly approved medicine that treats patients with a serious autoimmune condition.

ChemoCentryx is being purchased for $52 per share, or a 116% premium to its Wednesday closing price.

The centerpiece of Amgen’s acquisition is a pill called Tavneos that treats patients with ANCA-associated vasculitis, an autoimmune disease that causes inflammation, blockage, and damage to small blood vessels. People with the disorder are at high risk for organ damage, often in the kidneys and lungs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In